

Kindstar Global, IncellDx Reach Agreement to Bring Single-Cell Immuno-Oncology Products to China

San Carlos, California (Aug 5, 2019) Kindstar Global and IncellDx, Inc. have announced today that they have signed a Master Collaboration Agreement and Exclusive Distribution agreement for three of IncellDx's single-cell immuno-oncology and oncology diagnostic products: OncoTect iO Tumor Treatment Profile™, OncoTect iO Bladder™ and OncoBreast®. Under the terms of the agreement, the IncellDx tests will be used within the Kindstar Laboratory System in China, including Hong Kong and Macao.

The OncoTect iO Tumor Treatment Profile test refers to the IncellDx technology identifying PD-L1, EGFR, ALK and Cell Cycle; the OncoTect iO Bladder test refers to the IncellDx technology identifying bladder cancer and PD-L1 status from urine; and the OncoBreast test refers to the IncellDx technology identifying ER, PR, Her2 protein, Her2 mRNA and aneuploidy DNA simultaneously in breast samples. All of these assays can be performed in high throughput in less than 3 hours allowing timely information flow to physicians.

Dr. Shiang Huang, Founder and CEO of Kindstar, stated “Certainly we think this is a great opportunity and potential for both companies; and, we believe it will bring great benefits and applications for patients and physicians in the broad area of oncology in China”.

Dr. Bruce Patterson, Founder and CEO of IncellDx, stated “we are excited to broaden our presence in China with Kindstar from whom we have seen tremendous growth over the years. The scalability of our assays will make this opportunity a major growth driver for IncellDx in 2019 and beyond.”

About Kindstar Group

Kindstar Global Technology is the first and biggest leading-edge medical esoteric testing service group in China. It provides 3000+ tests in hematology, oncology, medical genetics, cardiovascular diseases, infectious diseases and autoimmune diseases to medical specialties including internal medicine department, surgery department, gynecology department and pediatrics department in more than 3000 hospitals. Kindstar also provides medical research, clinical trial services and translational medicine study services to physicians, medical science and technology institutions and pharmaceutical companies. Kindstar Global has been committed to leading China's esoteric testing technology and services, and improving China's specialty diagnosis and individualized health.

About IncellDx, Inc.

IncellDx, Inc, located at Menlo Park, California is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA *in situ* hybridization, and DNA cell cycle analysis. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care.

Contact for Kindstar:

Shiang Huang, CEO
shianghuang@kindstar.com.cn

Contact for IncellDx:

Chris Meda, Chief Business Officer
chrism@incelldx.com